Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Lorena Panaite, MBBS, Jordan Gauthier, MD, Paula Perkins, MS,PA-C, Jenna Voutsinas, MPH, Qian Vicky Wu, PhD, Angela Kirk, PA-C, Aisling Cearley, PA-C, Erin Mullane, DNP, Ryan D. Cassaday, MD, Hans-Peter Kiem, MDPhD, Victor A. Chow, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD, Brian G. Till, MD, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Mazyar Shadman, MDMPH

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134816

Published: 2020

Journal Articles

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Jordan Gauthier, MD MSc, Cassie Chou, MDPhD, Alexandre V. Hirayama, MD, Salvatore Fiorenza, MBBS, PhD, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Tinh-Doan Phi, BSc, Rachel Steinmetz, BSc, Abby Jamieson, BSc, Delaney R Kirchmeier, BSc, Henna N Di, BSc, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140120

Published: 2020

Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136440

Published: 2020

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Evandro D. Bezerra, MD, Jordan Gauthier, MD MSc, Alexandre V. Hirayama, MD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 201.

https://doi.org/10.1182/blood-2019-123807

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Merav Bar, MD, Julia Ruark, MD MPH, Erin Mullane, DNP, Nancy Cleary, BSc, Ana Cordeiro, MD, Evandro D. Bezerra, MD, Jenna M. Voutsinas, MPH, Bronwen E. Shaw, MD PhD, Qian Vicky Wu, PhD, Kathryn E Flynn, PhD, Stephanie J. Lee, MD MPH, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Jesse Fann

Blood (2019) 134 (Supplement_1): 4453.

https://doi.org/10.1182/blood-2019-122755

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Nina D. Shah, MD, Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD PhD, Mario Q. Marcondes, MD PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD, Krina K. Patel, MDMSc

Blood (2019) 134 (Supplement_1): 4459.

https://doi.org/10.1182/blood-2019-122494

Published: 2019

Journal Articles

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 2889.

https://doi.org/10.1182/blood-2019-124962

Published: 2019

Journal Articles

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

Cassie Chou, MD PhD, Simon Fraessle, Rachel Steinmetz, BSc, Reed M. Hawkins, BS, Tinh-Doan Phi, BS, Dirk Busch, Takahiro Miyazaki, Mario Q. Marcondes, MD PhD, Stanley R. Riddell, MD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 2866.

https://doi.org/10.1182/blood-2019-125960

Published: 2019

Journal Articles

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

Mazyar Shadman, MD, Jordan Gauthier, MD MSc, Sirin Khajavian, MD, Alexandre V. Hirayama, MD, Ryan C. Lynch, MD, Stephen D. Smith, MD, Chaitra S. Ujjani, MD, Victor A. Chow, MD, Hans-Peter Kiem, MD PhD, Brian G. Till, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 4294.

https://doi.org/10.1182/blood-2019-126269

Published: 2019

Journal Articles

Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

Krishna R. Juluri, MD PhD, Alexandre V. Hirayama, MD, Erin Mullane, DNP, Nancy Cleary, BSc, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Merav Bar, MD, Jordan Gauthier, MD MSc

Blood (2019) 134 (Supplement_1): 3229.

https://doi.org/10.1182/blood-2019-126922

Published: 2019

Journal Articles

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Mazyar Shadman, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Cameron J. Turtle, MBBS, PhD, Adam Greenbaum, MD PhD, Mary Redman, Cecilia Yeung, MD, Martina Sersch, MD PhD, Edus H. Warren, MD PhD, David G. Maloney, MD PhD, Brian G. Till, MD

Blood (2019) 134 (Supplement_1): 3235.

https://doi.org/10.1182/blood-2019-125102

Published: 2019

Journal Articles

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2018-99-116745

Published: 2018

Journal Articles

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2018-99-115126

Published: 2018

Journal Articles

Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells

Alyssa Sheih, PhD, Laila-Aicha Hanafi, PhD, Valentin Voillet, PhD, Hannah A. DeBerg, PhD, Reed M. Hawkins, BS, Masanao Yajima, PhD, Vivian Gersuk, PhD, Peter S. Linsley, PhD, Raphael Gottardo, PhD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 702.

https://doi.org/10.1182/blood-2018-99-111350

Published: 2018

Journal Articles

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Victor A. Chow, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R. Shustov, MD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Utkarsh H. Acharya, DO, Erin Mullane, DNP, Lindsay M. Hannan, MD MS, Jenna M. Voutsinas, MSc, Ted Gooley, PhD, Ryan C. Lynch, MD

Blood (2018) 132 (Supplement 1): 94.

https://doi.org/10.1182/blood-2018-99-110747

Published: 2018

Journal Articles

Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation

Alyssa Sheih, PhD, Jonathan L. Golob, MD, PhD, Abir Bhattacharyya, MBBS, Michael C. Wu, PhD, Aesha Vakil, MSc, Sujatha Srinivasan, PhD, Steven A. Pergam, MD MPH, David N. Fredricks, MD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2018-99-115158

Published: 2018

Journal Articles

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Blood (2018) 132 (Supplement 1): 281.

https://doi.org/10.1182/blood-2018-99-110561

Published: 2018

Journal Articles

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Blood (2018) 132 (Supplement 1): 299.

https://doi.org/10.1182/blood-2018-99-111061

Published: 2018

NARROW

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only